Due to the inhibition of the PI3K/AKT pathway, glycogen synthesis in the liver is reduced and blood glucose is increased, which promote the de novo synthesis of liver fatty acids and increase adrenoleukodystrophy (VLDL) secretion, leading to fatty liver and hyperlipidemia. Here, AKT1 is linked to hyperlipidemia.